1051 ET - There will be a debate around how conservative Doximity's guidance is until the company's typical upselling season kicks off in August, JPMorgan analysts say in a research note. At that point, Doximity will have better clarity into how the budgets of its pharmaceutical clients are shaping up, the analysts say. As of right now, the company's outlook assumes some weakness in cross-selling and upselling, they say. But management says it hasn't seen any indications yet of its market slowing, and that Doximity faces less risk than it used to now that just under 70% of the year's revenue is already under contract, the analysts say. (dean.seal@wsj.com)
(END) Dow Jones Newswires
May 16, 2025 10:51 ET (14:51 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。